Clinical Characteristics and Prognostic Influence Factors of Patients with AIDS-related Malignant Tumor

LEI Haike; LI Xiaosheng; LI Jieping; LIU Jun; XIAO Chunyan; WANG Ying; ZHANG Wei; LIU Yao; WU Yongzhong

doi:10.3971/j.issn.1000-8578.2022.21.1056

Cancer Research on Prevention and Treatment > 2022 > 49(5): 412-417. > DOI: 10.3971/j.issn.1000-8578.2022.21.1056

LEI Haike, LI Xiaosheng, LI Jieping, LIU Jun, XIAO Chunyan, WANG Ying, ZHANG Wei, LIU Yao, WU Yongzhong. Clinical Characteristics and Prognostic Influence Factors of Patients with AIDS-related Malignant Tumor[J]. Cancer Research on Prevention and Treatment, 2022, 49(5): 412-417. DOI: 10.3971/j.issn.1000-8578.2022.21.1056

Citation:

PDF (4827 KB)

Clinical Characteristics and Prognostic Influence Factors of Patients with AIDS-related Malignant Tumor

1.
Department of Appointment and Follow-up Center, Chongqing University Cancer Hospital, Chongqing 400030, China
2.
Medical Records and Statistics Room, Chongqing University Cancer Hospital, Chongqing 400030, China
3.
Department of Hematological Oncology Center, Chongqing University Cancer Hospital, Chongqing 400030, China
4.
Department of Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing 400030, China
5.
Deanery, Chongqing University Cancer Hospital, Chongqing 400030, China

Funding:

Chongqing Technology Innovation and Application Development Special Project cstc2019jscx-fxydX0008

Chongqing Performance Incentive and Guidance Project for Scientific Research Institutions cstc2020jxjl130016

More Information

Corresponding author:
ZHANG Wei, E-mail: cqzlyy@163.com

LIU Yao, E-mail: liuyao77@cqu.edu.cn
^*Contributed Equally as the First Author
Received Date: September 15, 2021
Revised Date: November 10, 2021
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To analyze the clinical characteristics and survival prognosis of patients with AIDS-related malignant tumor.
Methods
We retrospectively analyzed the data of 354 patients with AIDS-related malignant tumor. Univariate analysis was conducted by Log rank test and multivariate analysis was conducted by Cox proportional risk regression model.
Results
The average age of the patients was 54.10±12.96 years old. The ratio of male to female patients was 2.1:1. The number of patients with AIDS complicated with lymphoma was the most, accounting for 28.25%. The 1-, 3- and 5-year survival rates were 78.48%, 62.13% and 55.31%, respectively. Univariate analysis showed that there were statistical differences in prognosis of patients with different types of malignant tumor, age, gender, medical insurance type, number of admissions after diagnosis of AIDS, average length of stay, radiotherapy or not, leaving hospital according to medical advice. Multivariate analysis showed that gender, number of admissions after diagnosis of AIDS, average length of stay, proportion of out-of-pocket and leaving hospital according to medical advice were independent risk factors affecting the survival and prognosis of patients.
Conclusion
AIDS is easily complicated with lymphoma, lung cancer and cervical cancer. The patients received insufficient anti-tumor courses in hospital.
- HIV,
- Malignant tumor,
- Clinical features,
- Survival,
- Prognosis

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (21)

References

[1]	Trickey A, May MT, Gill MJ, et al. Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies[J]. Int J Cancer, 2020, 146(11): 3134-3146. doi: 10.1002/ijc.32895
[2]	Sellier P, Hamet G, Brun A, et al. COREVIH Ile-de-France-Est research group. Mortality of People Living with HIV in Paris Area from 2011 to 2015[J]. AIDS Res Hum Retroviruses, 2020, 36(5): 373-380. doi: 10.1089/aid.2019.0143
[3]	Qiao YC, Xu Y, Jiang DX, et al. Epidemiological analyses of regional and age differences of HIV/AIDS prevalence in China, 2004-2016[J]. Int J Infect Dis, 2019, 81: 215-220. doi: 10.1016/j.ijid.2019.02.016
[4]	王丽艳, 秦倩倩, 丁正伟, 等. 中国艾滋病全国疫情数据分析[J]. 中国艾滋病性病, 2017, 23(4): 330-333. [Wang LY, Qian QQ, Ding ZW, et al. Current situation of AIDS epidemic in China[J]. Zhongguo Ai Zi Bing Xing Bing, 2017, 23(4): 330-333. ]
[5]	Ji Y, Lu H. Malignancies in HIV-Infected and AIDS Patients[J]. Adv Exp Med Biol, 2017, 1018: 167-179.
[6]	吕繁, 陈方方. 艾滋病疫情估计及结果解读要点[J]. 中华流行病学杂志, 2019, 40(10): 1191-1196. doi: 10.3760/cma.j.issn.0254-6450.2019.10.004 [Lyu F, Chen FF. National HIV/AIDS epidemic estimation and interpretation in China[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2019, 40(10): 1191-1196. ] doi: 10.3760/cma.j.issn.0254-6450.2019.10.004
[7]	Li Z, Morano JP, Khoshnood K, et al. HIV-related stigma among people living with HIV/AIDS in rural Central China[J]. BMC Health Serv Res, 2018, 18(1): 453. doi: 10.1186/s12913-018-3245-0
[8]	Vangipuram R, Tyring SK. AIDS-Associated Malignancies[J]. Cancer Treat Res, 2019, 177: 1-21.
[9]	Costiniuk CT, Jenabian MA. Cannabinoids and inflammation: implications for people living with HIV[J]. AIDS, 2019, 33(15): 2273-2288. doi: 10.1097/QAD.0000000000002345
[10]	黄曦悦, 石明巧, 苟瑜, 等. 64例HIV/AIDS患者合并肿瘤临床特征分析[J]. 四川医学, 2018, 39(7): 743-747. [Huang XY, Shi MQ, Gou Y, et al. Analysis of the clinical features of 64 cases of HIV/AIDS patients with tumor[J]. Sichuan Yi Xue, 2018, 39(7): 743-747. ]
[11]	王红羚, 张天勇. 肿瘤患者HIV74例感染情况分析[J]. 重庆医学, 2012, 41(31): 3302-3304. doi: 10.3969/j.issn.1671-8348.2012.31.024 [Wang HL, Zhang TY. Survey of HIV infection in 74 tumor patients[J]. Chongqing Yi Xue, 2012, 41(31): 3302-3304. ] doi: 10.3969/j.issn.1671-8348.2012.31.024
[12]	张珂, 熊英, 吴立春, 等. 肿瘤患者中HIV感染状况的初步调查分析[J]. 肿瘤预防与治疗, 2011, 24(2): 83-85. [Zhang K, Xiong Y, Wu LC, et al. Investigation of HIV Infection Status in Cancer Patients[J]. Zhong Liu Fang Zhi Yu Zhi Liao, 2011, 24(2): 83-85. ]
[13]	Robbins HA, Shiels MS, Pfeiffer RM, et al. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States[J]. AIDS, 2014, 28(6): 881-890. doi: 10.1097/QAD.0000000000000163
[14]	中国疾病预防控制中心, 性病艾滋病预防控制中心, 性病控制中心. 2016年12月全国艾滋病性病疫情[J]. 中国艾滋病性病, 2017, 23(2): 93. [NCAIDS, NCSTD, China CDC. Update on the AIDS/STD epidemic in China in December, 2016[J]. Zhongguo Ai Zi Bing Xing Bing, 2017, 23(2): 93. ]
[15]	王袁, 张树敬, 蔡黎霞, 等. 肿瘤专科医院就诊患者HIV感染情况分析[J]. 中国皮肤性病学杂志, 2017, 31(4): 410-411, 418. [Wang Y, Zhang SJ, Cai NX, et al. Prevalence and Analysis of HIV Infection in Tumor Patients in Cancer Hospital[J]. Zhongguo Pi Fu Xing Bing Xue Za Zhi, 2017, 31(4): 410-411, 418. ]
[16]	倪明健, 陈学玲, 马媛媛, 等. 新疆维吾尔自治区艾滋病抗病毒治疗者不同性别死亡率及其影响因素分析[J]. 中华流行病学杂志, 2015, 36(9): 971-975. doi: 10.3760/cma.j.issn.0254-6450.2015.09.014 [Ni MJ, Chen XL, Ma YY, et al. Sex specific mortality in HIV/AIDS patients receiving antiretroviral therapy and risk factors in Xinjiang Uygur autonomous region[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2015, 36(9): 971-975. ] doi: 10.3760/cma.j.issn.0254-6450.2015.09.014
[17]	Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies[J]. Lancet HIV, 2017, 4(8): e349-e356. doi: 10.1016/S2352-3018(17)30066-8
[18]	国家癌症中心. 2019中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2021: 75. [National Cancer Center. Chinese cancer registry annual report 2019[M]. Beijing: People's Medical Publishing House, 2021: 75. ]
[19]	雷海科, 李小升, 赵玉兰, 等. 2011-2018年重庆多中心恶性肿瘤出院患者生存分析[J]. 中国肿瘤, 2020, 29(3): 192-198. [Lei HK, Li XS, Zhao YL, et al. Survival of Discharged Malignant Tumor Patients from Multi-centers in Chongqing from 2011 to 2018[J]. Zhongguo Zhong Liu, 2020, 29(3): 192-198. ]
[20]	胡俊华, 胡艳秋, 许红霞, 等. 佳木斯市艾滋病抗病毒治疗患者生存率及影响因素分析[J]. 中国现代医生, 2021, 59(19): 10-13. [Hu JH, Hu YQ, Xu HX, et al. Analysis of survival rate and influencing factors of AIDS patients treated with antiviral therapy in Jiamusi City[J]. Zhongguo Xian Dai Yi Sheng, 2021, 59(19): 10-13. ]
[21]	郑武, 赵丁源, 张薇, 等. 湖北省2008-2018年艾滋病抗病毒治疗患者生存及影响因素分析[J]. 中国热带医学, 2020, 20(5): 417-422. [Zheng W, Zhao DY, Zhang W, et al. Survival time and influence factors of HAART in Hubei, 2008-2018[J]. Zhongguo Re Dai Yi Xue, 2020, 20(5): 417-422. ]

[1]	LYU Xiaoxian, XU Qingxia. Correlation of Mean Corpuscular Volume with Clinical Features and Prognosis of Patients with Treatment-Related Acute Myeloid Leukemia[J]. Cancer Research on Prevention and Treatment, 2025, 52(5): 405-410. DOI: 10.3971/j.issn.1000-8578.2025.24.1214
[2]	CHEN Ruiqiu, ZHANG Zhilei, JIA Yuming, PENG Li. Research Progress on Prognostic Survival Assessment of Inflammatory Response Parameters in Ampullary Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(12): 1307-1312. DOI: 10.3971/j.issn.1000-8578.2022.22.0774
[3]	XU Wenjing, WANG Pei, MA Yueshi, GAO Liping. Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 375-380. DOI: 10.3971/j.issn.1000-8578.2021.20.0878
[4]	WU Ying, CHENG Fang. Prognosis of Male and Postmenopausal Female Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2020, 47(3): 190-193. DOI: 10.3971/j.issn.1000-8578.2020.19.0747
[5]	YUAN Ying, ZANG Li, YUE Zhijie, ZHANG Yizhuo, WANG Xiaofang. Clinical Features and Prognosis of 74 Cases of Lymphoblastic Lymphoma[J]. Cancer Research on Prevention and Treatment, 2018, 45(3): 154-159. DOI: 10.3971/j.issn.1000-8578.2018.17.0751
[6]	ZHANG Rui, LI Jing, SONG Yuzhi, JING Zhonghao, ZHEN Chanjun, WANG Shuoshuo, LIU Ming, QIAO Xueying. Prognosis of Clinical Stage ⅢA(N2) Non-small Cell Lung Cancer Patients Received Ming, QIAO Xueying[J]. Cancer Research on Prevention and Treatment, 2016, 43(6): 526-530. DOI: 10.3971/j.issn.1000-8578.2016.06.018
[7]	LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
[8]	MA Xiangtao. Paleopathology on History of Oncology[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 215-218. DOI: 10.3971/j.issn.1000-8578.2015.03.001
[9]	MAO Zhiyuan, XIONG Mei, REN Li, LI Dechang, YUE Ying, ZHENG Jichun. Pathological Factors for Prognosis of Extrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 777-780. DOI: 10.3971/j.issn.1000-8578.2014.07.019
[10]	XU Ping, LIU SHu-gang, CHEN Yu-ping, et al. Significance of clinical determination of serum VEGF in prognosis of malignant tumor[J]. Cancer Research on Prevention and Treatment, 2002, 29(04): 310-312. DOI: 10.3971/j.issn.1000-8578.3299

Cited By

Cited by

Periodical cited type(8)

1.	王艳，刘排行，李素红. 叙事干预为主的压力管理对艾滋病患儿情绪状态的影响. 中国健康心理学杂志. 2025(04): 529-533 .
2.	张莎，唐立，闵海燕，段月勋，张娅玲，张月华，陈石芬，樊珊珊，罗佳. HIV/AIDS合并肿瘤患者生命质量状况及影响因素. 中国艾滋病性病. 2024(01): 34-38 .
3.	高敏. 3例艾滋病合并膀胱癌患者行手术治疗后的护理经验. 医学理论与实践. 2024(06): 1036-1037 .
4.	亓露，李新新，郭巧丽，闫鹏，张岩红. HIV阳性女性感染高危型人乳头瘤病毒的调查分析. 临床医学. 2024(04): 54-56 .
5.	王宁，李刚，李丹，龚胜，袁晔，周君，陈朝琼，姚晓军. 食管癌合并HIV感染/AIDS患者临床特征及淋巴结转移的危险因素分析. 肿瘤预防与治疗. 2024(04): 328-334 .
6.	张媛媛，朱浩智，许南松，余金吨，邓创忠，黄丽华. 肿瘤专科医院2022年就诊患者常见传染病感染状况分析. 中山大学学报(医学科学版). 2024(04): 666-672 .
7.	李新新，亓露. 艾滋病合并宫颈病变患者细胞免疫状态及其高危型HPV感染率研究. 罕少疾病杂志. 2024(09): 137-138 .
8.	李丹，姚晓军. 食管癌合并HIV/AIDS的流行病学特征与诊治进展. 中国胸心血管外科临床杂志. 2024(11): 1684-1689 .

Other cited types(0)

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article views (1847) PDF downloads (605) Cited by(8)

Turn off MathJax

Article Contents

Abstract

References

Clinical Characteristics and Prognostic Influence Factors of Patients with AIDS-related Malignant Tumor